CAMBRIDGE, Mass., April 23,
2024 /PRNewswire/ -- Flare Therapeutics Inc., a
clinical-stage biotechnology company targeting transcription
factors to discover precision medicines for cancer and other
diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief
Executive Officer, effective immediately. Dr. Manion brings over
two decades of experience in pharmaceutical research and
development, having held leadership roles across several
biotechnology and pharmaceutical companies. He succeeds interim CEO
Abbie Celniker, Ph.D., a partner at
Third Rock Ventures, who will continue to serve as Chair of the
Company's Board of Directors.
"I am delighted to welcome Doug to FlareTx and want to
express my deepest confidence in his ability to lead the company
during this next stage of growth. Over the course of his career, he
has gained substantial company building and drug development
expertise, which will be invaluable as FlareTx continues to grow as
an organization and advances its clinical-stage pipeline and
capabilities in drugging transcription factors," said Dr. Celniker.
"I look forward to working with him and the leadership team as they
drive the company's strong momentum."
"There has been rapid growth at FlareTx since the company was
launched and I am excited for this opportunity to lead such an
exceptional and cross-functional team as we advance FX-909 toward
clinical proof of concept data in the second half of this year and
fully recognize the potential of our discovery engine as we seek to
change the paradigm in drugging transcription factors," said Dr.
Manion. "I share in the team's vision to rapidly transform this
novel science into approved medicines for people with cancer and
other diseases."
Dr. Manion joins Flare Therapeutics from Aclaris Therapeutics,
Inc. (NASDAQ: ACRS), where he was President and Chief
Executive Officer. Before that, he was Executive Vice President of
Research and Development at Arena Pharmaceuticals, Inc., where he
oversaw all research and development activities until its
acquisition by Pfizer Inc. Dr. Manion joined Arena after
serving as Chief Executive Officer of Kleo Pharmaceuticals, a
private immuno-oncology company, from 2017 until its acquisition by
Biohaven Holdings in January 2021.
Previously Dr. Manion was Senior Vice President, Head of Specialty
Development and Head of R&D Japan and China at Bristol-Myers Squibb. During his
11-year tenure at BMS, he held leadership roles overseeing global
clinical research, clinical development, pharmacovigilance and
biostatistics, across various therapeutic areas, including
virology, immunology, neurology, cardiology, metabolic diseases,
genetically-defined diseases and fibrosis. Dr. Manion's previous
biopharmaceutical experience includes progressive leadership roles
at GlaxoSmithKline, DuPont Pharmaceuticals, and DuPont Merck
Pharmaceuticals. He is Board Certified in Internal Medicine and
completed an Infectious Diseases Fellowship at the University of Ottawa in Ontario, Canada followed by post-doctoral
training at Massachusetts General Hospital and Harvard Medical School.
About Flare Therapeutics Inc.
Flare Therapeutics is a
biotechnology company exclusively focused on drugging transcription
factors (TFs) to fully unlock the therapeutic potential of this
previously elusive target class. Flare Therapeutics' integrated
discovery engine converges rich genetic, biochemical, and chemical
insights to reveal druggable pockets and identify small molecule
ligands capable of modulating TFs of high therapeutic potential.
Flare Therapeutics' proteomic and mass spectrometry platform is
powered by a proprietary library of electrophilic compounds unique
to Flare Therapeutics. The team has rapidly established an emerging
pipeline of programs, highlighted by FX-909, a first-in-class
investigational orally bioavailable small molecule inhibitor of
PPARG, a master regulator of the luminal lineage in advanced
urothelial cancer that is currently in a Phase I study. For more
information, please visit www.flaretx.com and follow us on
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/flare-therapeutics-appoints-douglas-manion-md-frcp-c-as-chief-executive-officer-302124574.html
SOURCE Flare Therapeutics